secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0001723128-24-000007
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal reports Q4 2023 net revenue $617M, GAAP loss $0.40 EPS; 2024 guidance $2.55-2.65B revenue
--------------------------------------------------------------------------------

- Q4 net revenue $617M (+1% YoY); GAAP net loss $99M ($0.40 loss per share); adjusted EBITDA $142M (-8% YoY).
- Full year 2023 net revenue $2.39B (+8%); GAAP net loss $84M; adjusted EBITDA $558M (+$44M YoY).
- 2024 guidance: net revenue $2.55-$2.65B; adjusted EBITDA $580-$620M.
- Generics Q4 revenue -9% YoY on order timing; AvKARE +38% on launches; Specialty +2%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312824000007/0001723128-24-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312824000007/amrx-20240301.htm
  HTML page:      https://secwatch.observer/filing/0001723128-24-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer